The global Minimal Residual Disease (MRD) market is booming, projected to reach \$1.9B in 2025, with a CAGR of 12.88% through 2033. Driven by advancements in PCR, FISH, and NGS technologies, this market offers lucrative opportunities for companies like Novartis, Adaptive Biotechnologies, and Amgen. Learn more about market trends, key players, and regional analysis.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.